drugset / Trial / NCT01329627
Feasibility Study of Metronomic Chemotherapy for Locally Advanced HER2-Negative Breast Cancer
Phase 2
Terminated
12 enrolled
Cancer Institute of the State of São Paulo
Fundação Faculdade de Medicina · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether weekly paclitaxel followed by weekly doxorubicin plus daily oral cyclophosphamide without granulocyte colony-stimulating factor (G-CSF) is feasible in the treatment of locally advanced HER2-negative breast cancer.
Timeline
- Start
- 2010-08
- Primary completion
- 2011-08
- Completion
- 2012-08
Outcome
Outcome not reported
Stopped: “Toxicity”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 100 mg | Oral |
| Subject | Doxorubicin | Other / unclassified | 24 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 100 mg/m2 | — |